文献速递血脂与心血管预防

辛伐他汀相关肌病的独立危险因素及其与其他肌肉症状的相关性

Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom.
PubMed 文献 · Eur Heart J · 2020-01-01

这项观察性分析纳入58 390例接受辛伐他汀平均3.4年治疗的血管疾病患者,其中171例为临床判定的肌病,15 208例为其他肌肉症状。Cox模型识别出辛伐他汀剂量、族裔、性别、年龄、BMI、糖尿病药物治疗及合用烟酸-拉罗匹仑、维拉帕米、β受体阻滞剂、地尔硫䓬和利尿剂等独立危险因素,组合风险评分最高与最低三分位间风险差异超过30倍(HR 34.35,95%CI 12.73-92.69),但该评分与其他肌肉症状无关(P=0.93)。

要点

  • 辛伐他汀相关肌病绝对发生率低,为9/10 000人年。
  • 剂量、族裔、性别、年龄、BMI、糖尿病及多种合并用药为独立危险因素。
  • 肌病风险评分可识别高危患者,但与其它肌肉症状无关。

核心结论

  • 辛伐他汀相关肌病绝对风险低,但可通过风险评分识别高危个体以指导患者管理。
  • 肌病风险评分与其他肌肉症状无关,支持他汀不导致绝大多数报告肌肉症状的随机安慰剂对照证据。

研究设计与样本

  • 观察性分析,纳入58 390例接受辛伐他汀平均3.4年治疗的血管疾病患者。
  • 分别分析171例临床判定肌病(不明原因肌肉疼痛或无力伴肌酸激酶>10倍正常上限)和15 208例其他肌肉症状。
  • 采用Cox比例风险模型识别肌病独立预测因素。

主要发现

  • 肌病发生率为9/10 000人年辛伐他汀治疗。
  • 独立危险因素包括辛伐他汀剂量、族裔、性别、年龄、体重指数、药物治疗的糖尿病、合用烟酸-拉罗匹仑、维拉帕米、β受体阻滞剂、地尔硫䓬和利尿剂。
  • 该风险评分与其他报告的肌肉症状无关(P across thirds=0.93)。
  • SLCO1B1基因型与肌病相关,但与其他肌肉症状无关。

临床怎么用

  • 对接受辛伐他汀治疗的患者,可评估剂量、族裔、性别、年龄、BMI、糖尿病及合并用药等危险因素以识别肌病高危个体。
  • 肌病风险评分不宜用于解释或预测其他类型肌肉症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Statins are widely used to prevent cardiovascular events, but little is known about the impact of different risk factors for statin-related myopathy or their relevance to reports of other types of muscle symptom. METHODS AND RESULTS: An observational analysis was undertaken of 171 clinically adjudicated cases of myopathy (defined as unexplained muscle pain or weakness with creatine kinase >10× upper limit of normal) and, separately, of 15 208 cases of other muscle symptoms among 58 390 individuals with vascular disease treated with simvastatin for a mean of 3.4 years. Cox proportional hazards models were used to identify independent predictors of myopathy. The rate of myopathy was low: 9 per 10 000 person-years of simvastatin therapy. Independent risk factors for myopathy included: simvastatin dose, ethnicity, sex, age, body mass index, medically treated diabetes, concomitant use of niacin-laropiprant, verapamil, beta-blockers, diltiazem and diuretics. In combination, these risk factors predicted more than a 30-fold risk difference between the top and bottom thirds of a myopathy risk score (hazard ratio : 34.35, 95% CI: 12.73-92.69, P across thirds = 9·1 × 10-48). However, despite the strong association with myopathy, this score was not associated with the other reported muscle symptoms (P across thirds = 0.93). Likewise, although SLCO1B1 genotype was associated with myopathy, it was not associated with other muscle symptoms. CONCLUSIONS: The absolute risk of simvastatin-related myopathy is low, but individuals at higher risk can be identified to help guide patient management. The lack of association of the myopathy risk score with other muscle symptoms reinforces randomized placebo-controlled evidence that statins do not cause the vast majority of reported muscle symptoms.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Hopewell JC, Offer A, Haynes R, et al. Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. Eur Heart J. 2020. PMID: 32702748. doi:10.1093/eurheartj/ehaa574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。